Professor Grant Stewart
Professor Grant Stewart is pleased to consider applications from prospective PhD students.
Professor Stewart is an academic surgeon at the University of Cambridge, with a focus on developing and promoting surgery related clinical trials and translational research. Grant has a specific interest in optimising management of patients with initially localised renal cancer, an area of great need within the disease. In order to make practice changing developments in this area Professor Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical excellence in managing renal cancer at Addenbrooke’s Hospital, Cambridge. To deliver on the above goals, Grant coordinates the Cambridge Renal Cancer Collaboration (CamRenCan) a group of over 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cancer research. His research metrics are: £52 million research grant/clinical trial income and 147 peer reviewed publications.
Professor Stewart took up the Professorship in Surgical Oncology in 2020 having moved to Cambridge in October 2015 from a post as Senior Lecturer in Urological Surgery at the University of Edinburgh where he led the Edinburgh Urological Cancer Group. Grant developed and co-directs the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), a Scotland-wide kidney cancer biorepository of 1200 patients with high quality clinical data linkage.
Professor Stewart chairs the Renal Cancer Surgical Subgroup of the National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group, Co-Chair of the Renal Cross Channel Group, sits on the Medical Advisory Board for CMR Surgical, is Chair of the Scientific and Education Committee of The Urology Foundation, is a member of the Clinical Expert Review Panel of Cancer Research UK and is CI/PI for several renal cancer clinical trials. Grant is Programme Director of the University of Edinburgh, Urology ChM.
kidney cancer; renal cell cancer; RCC; adjuvant; neoadjuvant; window-of-opportunity; clinical trials; heterogeneity; localised disease; minimal residual disease
Symplectic Elements feed provided by Research Information, University of Cambridge
S. Syafruddin, P. Rodrigues, E. Vojtasova, S. Patel, M. N. Zaini, J. Burge, A. Warren, G.D Stewart, T. Eisen, D. Bihary, S. Samarajiwa, S. Vanharanta. A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma. Nature Communications (IF=12.4). 2019.
S.H. Rossi, C. Blick, C. Handforth, J.E. Brown, G.D. Stewart, on behalf of the Renal Cancer Gap Analysis Collaborative. Essential research priorities in renal cancer: a modified Delphi consensus statement. European Urology Focus. 2019.
S. Dabestani, C. Beisland, G.D. Stewart, K. Bensalah, E. Gudmundsson, T.B. Lam, W. Gietzmann, P. Zakikhani, L. Marconi, S. Fernandéz-Pello, S. Monagas, S.P. Williams, C. Torbrand, T. Powles, E. Van Werkhoven, R. Meijer, A. Volpe, M. Staehler, B. Ljungberg, A. Bex. Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European multicentre database (RECUR). European Urology. 2018.
F. Mouliere, D. Chandrananda, A.M. Piskorz, E.K. Moore, J. Morris, L. Barlebo Ahlborn, R. Mair, T. Goranova, F. Marass, K. Heider, J.C. M. Wan, A. Supernat, I. Hudecova, I. Gounaris, S. Ros, M. Jimenez-Linan, J. Garcia-Corbacho, K. Patel, O. Østrup, S. Murphy, M.D. Eldridge, D. Gale, G.D. Stewart, J. Burge, W.N. Cooper, M.S. van der Heijden, C.E. Massie, C. Watts, P. Corrie, S. Pacey, K. Brindle, R. Baird, M. Mau-Sørensen, C.A. Parkinson, C.G. Smith, J.D. Brenton, N. Rosenfeld. Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine. 2018. 10(466).
M.D. Young, T.J. Mitchell, F.A. Vieira Braga, M.G.B. Tran, B.J. Stewart, J. Ferdinand, G. Collord, R.A. Botting, D-M. Popescu, K.W. Loudon, R. Vento-Tormo, E. Stephenson, A. Cagan, S. Farndon, M. Del Castillo Velasco-Herrera, C. Guzzo, N. Richoz, L. Mamanova, T. Aho, J.N. Armitage, A.C.P. Riddick, I. Mushtaq, S. Farrell, D. Rampling, J. Nicholson, A. Filby, J. Burge, S. Lisgo, P.H. Maxwell, S. Lindsay, A.Y. Warren, G.D. Stewart, N. Sebire, N. Coleman, M. Haniffa, S. Teichmann, M. Clatworthy, S. Behjati. Single cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018; 361: 594–599.
P. Rodrigues, S.A. Patel, L. Harewood, I. Olan, E. Vojtasova, S.E. Syafruddin, M.N. Zaini, E.K. Richardson, J. Burge, A.Y. Warren, G.D. Stewart, K. Saeb-Parsy, S.A. Samarajiwa, S. Vanharanta. NF-kappaB-dependent lymphoid enhancer co-option promotes renal carcinoma metastasis. Cancer Discovery. 2018. 8:850-865.
T.J. Mitchell, S. Turajlic, A. Rowan, D. Nicol, J.H.R. Farmery, T. O’Brien, I. Martincorena, P. Tarpey, N. Angelopoulos, L.R. Yates, A.P. Butler, K. Raine, G.D. Stewart, B. Challacombe, A. Fernando, J. I. Lopez, S. Hazell, A. Chandra, S. Chowdhury, S. Rudman, A. Soultati, G. Stamp, N. Fotiadis, L. Pickering, L. Au, L. Spain, J. Lynch, M. Stares, J. Teague, F. Maura, D.C. Wedge, S. Horswell, T. Chambers, K. Litchfield, H. Xu, A. Stewart, R. Elaidi, S. Oudard, N. McGranahan, I. Csabai, M. Gore, P.A. Futreal, J. Larkin, A.G. Lynch, Z. Szallasi, C. Swanton, P.J. Campbell, on behalf of the Renal TRACERx consortium. Timing the landmark events in the evolution of clear cell renal cell carcinoma: TRACERx Renal. Cell. 2018; 173(3): 611-623.
A.L.R. Lubbock, G.D. Stewart (joint 1st author), F.C. O’Mahony, A. Laird, P. Mullen, M. O’Donnell, T. Powles, D.J. Harrison, I.M. Overton. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine. 2017. 15(1):118.
S.H. Rossi, R. Hsu, C. Blick, V. Goh, P. Nathan, D. Nicol, S. Fleming, M. Sweeting, E.C.F. Wilson, G.D. Stewart. A meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals. British Journal of Surgery. 2017; 104: 648–659.
G.D. Stewart, F.C. O’Mahony, A. Laird, L. Eory, A.L.R. Lubbock, A. Mackay, J. Nanda, M. O’Donnell, P. Mullen, S.A. McNeill, A.C.P. Riddick, D. Berney, A. Bex, M. Aitchison, I.M. Overton, D.J. Harrison, T. Powles. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clinical Cancer Research. 2015; 21(18): 4212–23.
G.D. Stewart, F.C. O’Mahony, A. Laird, S. Rashid, S.A. Martin, L. Eory, A.L.R. Lubbock, J. Nanda, M. O’Donnell, A. Mackay, P. Mullen, S.A. McNeill, A.C.P. Riddick, M. Aitchison, D. Berney, A. Bex, I.M. Overton, D.J. Harrison, T. Powles. Carbonic anhydrase 9 expression increases with VEGF targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. European Urology. 2014; 66: 956-963.
K. Sharpe, G.D. Stewart (joint 1st author), A. Mackay, C. Van Neste, C. Rofe, D.M. Berney, I. Kayani, A. Bex, E. Wan, F. O’Mahony, M. O’Donnell, S. Chowdhury, R. Doshi, C. Ho Yen, M. Gerlinger, D. Baker, N.R. Smith, B.R. Davies, A. Sahdev, E. Boleti, T. de Meyer, W. Van Criekinge, L. Beltran, Y-J. Lu, D. Harrison, A.R. Reynolds, T. Powles. The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clinical Cancer Research. 2013; 19: 6924-6934.